Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Non-Current Liabilities (2025)

Benitec Biopharma has reported Total Non-Current Liabilities over the past 1 years, most recently at $3.3 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $3.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $3.3 million (changed N/A YoY), and the annual figure for FY2025 was $2.3 million, changed.
  • Total Non-Current Liabilities reached $3.3 million in Q4 2025 per BNTC's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $3.3 million in Q4 2025 and bottomed at $2.3 million in Q2 2025.